107 related articles for article (PubMed ID: 25376110)
1. Integration of a postoperative calcitonin measurement into an anatomical staging system improves initial risk stratification in medullary thyroid cancer.
Yang JH; Lindsey SC; Camacho CP; Valente FO; Germano-Neto F; Machado AL; Mamone MC; Brodskyn F; Biscolla RP; Tuttle RM; Dias-da-Silva MR; Maciel RM
Clin Endocrinol (Oxf); 2015 Dec; 83(6):938-42. PubMed ID: 25376110
[TBL] [Abstract][Full Text] [Related]
2. Dynamic risk stratification for medullary thyroid cancer according to the response to initial therapy.
Kwon H; Kim WG; Jeon MJ; Song DE; Lee YM; Sung TY; Chung KW; Yoon JH; Hong SJ; Baek JH; Lee JH; Kim TY; Kim WB; Shong YK
Endocrine; 2016 Jul; 53(1):174-81. PubMed ID: 26754662
[TBL] [Abstract][Full Text] [Related]
3. Response to initial therapy predicts clinical outcomes in medullary thyroid cancer.
Lindsey SC; Ganly I; Palmer F; Tuttle RM
Thyroid; 2015 Feb; 25(2):242-9. PubMed ID: 25338223
[TBL] [Abstract][Full Text] [Related]
4. Ultrasonographic Features of Medullary Thyroid Carcinoma: Do they Correlate with Pre and PostOperative Calcitonin Levels?
Cho KE; Gweon HM; Park AY; Yoo MR; Kim J; Youk JH; Park YM; Son EJ
Asian Pac J Cancer Prev; 2016; 17(7):3357-62. PubMed ID: 27509975
[TBL] [Abstract][Full Text] [Related]
5. Medullary thyroid cancer outcomes in patients with undetectable versus normalized postoperative calcitonin levels.
Fanget F; Demarchi MS; Maillard L; Lintis A; Decaussin M; Lifante JC
Br J Surg; 2021 Sep; 108(9):1064-1071. PubMed ID: 33899100
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes of patients with hypercalcitoninemia after initial treatment for medullary thyroid cancer and postoperative serum calcitonin cutoffs for predicting structural recurrence.
Cho YY; Jang HW; Jang JY; Kim TH; Choe JH; Kim JH; Kim JS; Kim SW; Chung JH
Head Neck; 2016 Oct; 38(10):1501-8. PubMed ID: 27062421
[TBL] [Abstract][Full Text] [Related]
7. Postoperative biochemical remission of serum calcitonin is the best predictive factor for recurrence-free survival of medullary thyroid cancer: a large-scale retrospective analysis over 30 years.
Jung KY; Kim SM; Yoo WS; Kim BW; Lee YS; Kim KW; Lee KE; Jeong JJ; Nam KH; Lee SH; Hah JH; Chung WY; Yi KH; Park DJ; Youn YK; Sung MW; Cho BY; Park CS; Park YJ; Chang HS
Clin Endocrinol (Oxf); 2016 Apr; 84(4):587-97. PubMed ID: 26175307
[TBL] [Abstract][Full Text] [Related]
8. Rethinking the Current American Joint Committee on Cancer TNM Staging System for Medullary Thyroid Cancer.
Adam MA; Thomas S; Roman SA; Hyslop T; Sosa JA
JAMA Surg; 2017 Sep; 152(9):869-876. PubMed ID: 28636692
[TBL] [Abstract][Full Text] [Related]
9. Postoperative Nomogram for Predicting Cancer-Specific Mortality in Medullary Thyroid Cancer.
Ho AS; Wang L; Palmer FL; Yu C; Toset A; Patel S; Kattan MW; Tuttle RM; Ganly I
Ann Surg Oncol; 2015 Aug; 22(8):2700-6. PubMed ID: 25366585
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma.
Barbet J; Campion L; Kraeber-Bodéré F; Chatal JF;
J Clin Endocrinol Metab; 2005 Nov; 90(11):6077-84. PubMed ID: 16091497
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Follow-up in Medullary Thyroid Carcinoma.
Raue F; Frank-Raue K
Recent Results Cancer Res; 2015; 204():207-25. PubMed ID: 26494391
[TBL] [Abstract][Full Text] [Related]
12. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders.
Elisei R; Bottici V; Luchetti F; Di Coscio G; Romei C; Grasso L; Miccoli P; Iacconi P; Basolo F; Pinchera A; Pacini F
J Clin Endocrinol Metab; 2004 Jan; 89(1):163-8. PubMed ID: 14715844
[TBL] [Abstract][Full Text] [Related]
13. Serum calcitonin nadirs to undetectable levels within 1 month of curative surgery in medullary thyroid cancer.
Andrade F; Rondeau G; Boucai L; Zeuren R; Shaha AR; Ganly I; Vaisman F; Corbo R; Tuttle M
Arch Endocrinol Metab; 2019; 63(2):137-141. PubMed ID: 30916162
[TBL] [Abstract][Full Text] [Related]
14. Spontaneous Deceleration and Acceleration of Growth Rate in Medullary Thyroid Carcinomas Suggested by Changes in Calcitonin Doubling Times Over Long-Term Surveillance.
Miyauchi A; Kudo T; Kihara M; Oda H; Ito Y; Miya A
World J Surg; 2019 Feb; 43(2):504-512. PubMed ID: 30229381
[TBL] [Abstract][Full Text] [Related]
15. Routine measurement of serum calcitonin is useful for early detection of medullary thyroid carcinoma in patients with nodular thyroid diseases.
Hahm JR; Lee MS; Min YK; Lee MK; Kim KW; Nam SJ; Yang JH; Chung JH
Thyroid; 2001 Jan; 11(1):73-80. PubMed ID: 11272100
[TBL] [Abstract][Full Text] [Related]
16. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma.
Pacini F; Fontanelli M; Fugazzola L; Elisei R; Romei C; Di Coscio G; Miccoli P; Pinchera A
J Clin Endocrinol Metab; 1994 Apr; 78(4):826-9. PubMed ID: 8157706
[TBL] [Abstract][Full Text] [Related]
17. Results of surgical treatment of sporadic medullary thyroid carcinoma following routine measurement of serum calcitonin.
Mirallié E; Iacobone M; Sebag F; Henry JF
Eur J Surg Oncol; 2004 Sep; 30(7):790-5. PubMed ID: 15296996
[TBL] [Abstract][Full Text] [Related]
18. Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy.
Vaisman F; Momesso D; Bulzico DA; Pessoa CH; Dias F; Corbo R; Vaisman M; Tuttle RM
Clin Endocrinol (Oxf); 2012 Jul; 77(1):132-8. PubMed ID: 22248037
[TBL] [Abstract][Full Text] [Related]
19. Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d'Etudes des Tumeurs a Calcitonine (GETC).
Cohen R; Campos JM; Salaün C; Heshmati HM; Kraimps JL; Proye C; Sarfati E; Henry JF; Niccoli-Sire P; Modigliani E
J Clin Endocrinol Metab; 2000 Feb; 85(2):919-22. PubMed ID: 10690910
[TBL] [Abstract][Full Text] [Related]
20. Surgical strategy for the treatment of sporadic medullary thyroid carcinoma: our experience.
Lupone G; Antonino A; Rosato A; Zenone P; Iervolino EM; Grillo M; De Palma M
G Chir; 2012; 33(11-12):395-9. PubMed ID: 23140924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
